Top

Published in:

01-05-2016 | Topic Review

Positron emission tomography of high-grade gliomas

Author: Guido Frosina

Published in: Journal of Neuro-Oncology | Issue 3/2016

Abstract

High-grade gliomas [HGG (WHO grades III–IV)] are almost invariably fatal. Imaging of HGG is important for orientating diagnosis, prognosis and treatment planning and is crucial for development of novel, more effective therapies. Given the potentially unlimited number of usable tracing molecules and the elevated number of available radionuclides, PET allows gathering multiple informations on HGG including data on tissue metabolism and drug pharmacokinetics. PET studies on the diagnosis, prognosis and treatment of HGG carried out by most frequently used tracers and radionuclides (¹¹C and ¹⁸F) and published in 2014 have been reviewed. These studies demonstrate that a thorough choice of tracers may confer elevated diagnostic and prognostic power to PET imaging of HGG. They also suggest that a combination of PET and MRI may give the most complete and reliable imaging information on HGG and that research on hybrid PET/MRI may be paying back in terms of improved diagnosis, prognosis and treatment planning of these deadly tumours.

Ahmed R, Oborski MJ, Hwang M, Lieberman FS, Mountz JM (2014) Malignant gliomas: current perspectives in diagnosis, treatment, and early response assessment using advanced quantitative imaging methods. Cancer Manag Res 6:149–170PubMedPubMedCentral

Heiss WD (2014) PET in gliomas. Overview of current studies. Nuklearmedizin 53:163–171CrossRefPubMed

Dhermain F (2014) Radiotherapy of high-grade gliomas: current standards and new concepts, innovations in imaging and radiotherapy, and new therapeutic approaches. Chin J Cancer 33:16–24CrossRefPubMedPubMedCentral

Demetriades AK, Almeida AC, Bhangoo RS, Barrington SF (2014) Applications of positron emission tomography in neuro-oncology: a clinical approach. Surgeon 12:148–157CrossRefPubMed

Sanchez-Crespo A, Andreo P, Larsson SA (2004) Positron flight in human tissues and its influence on PET image spatial resolution. Eur J Nucl Med Mol Imaging 31:44–51CrossRefPubMed

Christensen M, Kamson DO, Snyder M, Kim H, Robinette NL, Mittal S et al (2014) Tryptophan PET-defined gross tumor volume offers better coverage of initial progression than standard MRI-based planning in glioblastoma patients. J Radiat Oncol 3:131–138CrossRefPubMedPubMedCentral

Kamson DO, Lee TJ, Varadarajan K, Robinette NL, Muzik O, Chakraborty PK et al (2014) Clinical significance of tryptophan metabolism in the nontumoral hemisphere in patients with malignant glioma. J Nucl Med 55(10):1605–1610CrossRefPubMedPubMedCentral

Kamson DO, Mittal S, Robinette NL, Muzik O, Kupsky WJ, Barger GR et al (2014) Increased tryptophan uptake on PET has strong independent prognostic value in patients with a previously treated high-grade glioma. Neuro Oncol 16(10):1373–1383CrossRefPubMedPubMedCentral

Santoni M, Nanni C, Bittoni A, Polonara G, Paccapelo A, Trignani R et al (2014) [(11) C]-methionine positron emission tomography in the postoperative imaging and followup of patients with primary and recurrent gliomas. ISRN Oncol 2014:463152PubMedPubMedCentral

10.

Choi H, Paeng JC, Cheon GJ, Park CK, Choi SH, Min HS et al (2014) Correlation of 11C-methionine PET and diffusion-weighted MRI: is there a complementary diagnostic role for gliomas? Nucl Med Commun 35:720–726CrossRefPubMed

11.

Tietze A, Boldsen JK, Mouridsen K, Ribe L, Dyve S, Cortnum S et al (2014) Spatial distribution of malignant tissue in gliomas: Correlations of 11C-L-methionine positron emission tomography and perfusion- and diffusion-weighted magnetic resonance imaging. Acta Radiol 56(9):1135–1144CrossRefPubMed

12.

Schinkelshoek M, Lopci E, Clerici E, Alongi F, Mancosu P, Rodari M et al (2014) Impact of 11C-methionine positron emission tomography/computed tomography on radiation therapy planning and prognosis in patients with primary brain tumors. Tumori 100:636–644PubMed

13.

Suchorska B, Jansen NL, Linn J, Kretzschmar H, Janssen H, Eigenbrod S et al (2015) Biological tumor volume in 18FET-PET before radiochemotherapy correlates with survival in GBM. Neurology 84:710–719CrossRefPubMed

14.

Navarria P, Reggiori G, Pessina F, Ascolese AM, Tomatis S, Mancosu P et al (2014) Investigation on the role of integrated PET/MRI for target volume definition and radiotherapy planning in patients with high grade glioma. Radiother Oncol 112:425–429CrossRefPubMed

15.

Takenaka S, Asano Y, Shinoda J, Nomura Y, Yonezawa S, Miwa K et al (2014) Comparison of (11)C-methionine, (11)C-choline, and (18)F-fluorodeoxyglucose-PET for distinguishing glioma recurrence from radiation necrosis. Neurol Med Chir (Tokyo) 54:280–289CrossRef

16.

Wang X, Hu X, Xie P, Li W, Li X, Ma L (2015) Comparison of magnetic resonance spectroscopy and positron emission tomography in detection of tumor recurrence in posttreatment of glioma: A diagnostic meta-analysis. Asia Pac J Clin Oncol 11(2):97–105CrossRefPubMed

17.

Okita Y, Nonaka M, Shofuda T, Kanematsu D, Yoshioka E, Kodama Y et al (2014) C-methionine uptake correlates with MGMT promoter methylation in nonenhancing gliomas. Clin Neurol Neurosurg 125C:212–216CrossRef

18.

Gibellini F, Smith TK (2010) The kennedy pathway–de novo synthesis of phosphatidylethanolamine and phosphatidylcholine. IUBMB Life 62:414–428CrossRefPubMed

19.

He H, Nilsson CL, Emmett MR, Marshall AG, Kroes RA, Moskal JR et al (2010) Glycomic and transcriptomic response of GSC11 glioblastoma stem cells to STAT3 phosphorylation inhibition and serum-induced differentiation. J Proteome Res 9:2098–2108CrossRefPubMed

20.

Li W, Ma L, Wang X, Sun J, Wang S, Hu X (2014) C-choline PET/CT tumor recurrence detection and survival prediction in post-treatment patients with high-grade gliomas. Tumour Biol 35(12):12353–12360CrossRefPubMed

21.

Tran LB, Bol A, Labar D, Karroum O, Bol V, Jordan B et al (2014) Potential role of hypoxia imaging using (18)F-FAZA PET to guide hypoxia-driven interventions (carbogen breathing or dose escalation) in radiation therapy. Radiother Oncol 113:204–209CrossRefPubMed

22.

Kawai N, Lin W, Cao WD, Ogawa D, Miyake K, Haba R et al (2014) Correlation between (18)F-fluoromisonidazole PET and expression of HIF-1alpha and VEGF in newly diagnosed and recurrent malignant gliomas. Eur J Nucl Med Mol Imaging 41:1870–1878CrossRefPubMed

23.

Hanaoka K, Watabe T, Naka S, Kanai Y, Ikeda H, Horitsugi G et al (2014) FBPA PET in boron neutron capture therapy for cancer: Prediction of B concentration in the tumor and normal tissue in a rat xenograft model. EJNMMI Res 4(1):70CrossRefPubMedPubMedCentral

24.

Yang FY, Chang WY, Li JJ, Wang HE, Chen JC, Chang CW (2014) Pharmacokinetic analysis and uptake of 18F-FBPA-fr after ultrasound-induced blood-brain barrier disruption for potential enhancement of boron delivery for neutron capture therapy. J Nucl Med 55:616–621CrossRefPubMed

25.

Bolcaen J, Descamps B, Deblaere K, Boterberg T, De Vos Pharm F, Kalala JP et al (2015) F-fluoromethylcholine (FCho), F-fluoroethyltyrosine (FET), and F-fluorodeoxyglucose (FDG) for the discrimination between high-grade glioma and radiation necrosis in rats: a PET study. Nucl Med Biol 42(1):38–45CrossRefPubMed

26.

Imani F, Boada FE, Lieberman FS, Davis DK, Mountz JM (2014) Molecular and metabolic pattern classification for detection of brain glioma progression. Eur J Radiol 83:e100–e105CrossRefPubMedPubMedCentral

27.

Herminghaus S, Pilatus U, Moller-Hartmann W, Raab P, Lanfermann H, Schlote W et al (2002) Increased choline levels coincide with enhanced proliferative activity of human neuroepithelial brain tumors. NMR Biomed 15:385–392CrossRefPubMed

28.

Yoon JH, Kim JH, Kang WJ, Sohn CH, Choi SH, Yun TJ et al (2014) Grading of cerebral glioma with multiparametric MR imaging and 18F-FDG-PET: concordance and accuracy. Eur Radiol 24:380–389CrossRefPubMed

29.

Jansen MH, Kloet RW, van Vuurden DG, van Zanten SEV, Witte BI, Goldman S et al (2014) 18 F-FDG PET standard uptake values of the normal pons in children: establishing a reference value for diffuse intrinsic pontine glioma. EJNMMI Res 4:8-219X-4-8CrossRef

30.

Jansen NL, Suchorska B, Wenter V, Eigenbrod S, Schmid-Tannwald C, Zwergal A et al (2014) Dynamic 18F-FET PET in newly diagnosed astrocytic low-grade glioma identifies high-risk patients. J Nucl Med 55:198–203CrossRefPubMed

31.

Goda JS, Dutta D, Raut N, Juvekar SL, Purandare N, Rangarajan V et al (2013) Can multiparametric MRI and FDG-PET predict outcome in diffuse brainstem glioma? A report from a prospective phase-II study. Pediatr Neurosurg 49:274–281CrossRefPubMed

32.

Schwarzenberg J, Czernin J, Cloughesy TF, Ellingson BM, Pope WB, Grogan T et al (2014) Treatment response evaluation using 18F-FDOPA PET in patients with recurrent malignant glioma on bevacizumab therapy. Clin Cancer Res 20:3550–3559CrossRefPubMedPubMedCentral

33.

Karunanithi S, Sharma P, Kumar A, Gupta DK, Khangembam BC, Ballal S et al (2014) Can (18)F-FDOPA PET/CT predict survival in patients with suspected recurrent glioma? A prospective study. Eur J Radiol 83:219–225CrossRefPubMed

34.

Morana G, Piccardo A, Milanaccio C, Puntoni M, Nozza P, Cama A et al (2014) Value of 18F-3,4-dihydroxyphenylalanine PET/MR image fusion in pediatric supratentorial infiltrative astrocytomas: a prospective pilot study. J Nucl Med 55:718–723CrossRefPubMed

35.

Wang L, Lieberman BP, Ploessl K, Kung HF (2014) Synthesis and evaluation of (1)(8)F labeled FET prodrugs for tumor imaging. Nucl Med Biol 41:58–67CrossRefPubMedPubMedCentral

36.

Sweeney R, Polat B, Samnick S, Reiners C, Flentje M, Verburg FA (2014) O-(2-[(18)F]fluoroethyl)-l-tyrosine uptake is an independent prognostic determinant in patients with glioma referred for radiation therapy. Ann Nucl Med 28:154–162CrossRefPubMed

37.

Munck Af Rosenschold P, Costa J, Engelholm SA, Lundemann MJ, Law I, Ohlhues L et al (2015) Impact of [18F]-fluoro-ethyL-tyrosine PET imaging on target definition for radiation therapy of high-grade glioma. Neuro Oncol 17:757–763CrossRefPubMed

38.

Piroth MD, Pinkawa M, Holy R, Klotz J, Schaar S, Stoffels G et al (2012) Integrated boost IMRT with FET-PET-adapted local dose escalation in glioblastomas. results of a prospective phase II study. Strahlenther Onkol 188:334–339CrossRefPubMed

39.

Niyazi M, Jansen NL, Rottler M, Ganswindt U, Belka C (2014) Recurrence pattern analysis after re-irradiation with bevacizumab in recurrent malignant glioma patients. Radiat Oncol 9:299CrossRefPubMedPubMedCentral

40.

Pyka T, Gempt J, Ringel F, Huttinger S, van Marwick S, Nekolla S et al (2014) Prediction of glioma recurrence using dynamic 18F-fluoroethyltyrosine PET. AJNR Am J Neuroradiol 35(10):1924–1929CrossRefPubMed

41.

Filss CP, Galldiks N, Stoffels G, Sabel M, Wittsack HJ, Turowski B et al (2014) Comparison of 18F-FET PET and perfusion-weighted MR imaging: a PET/MR imaging hybrid study in patients with brain tumors. J Nucl Med 55:540–545CrossRefPubMed

42.

Dunet V, Maeder P, Nicod-Lalonde M, Lhermitte B, Pollo C, Bloch J et al (2014) Combination of MRI and dynamic FET PET for initial glioma grading. Nuklearmedizin 53:155–161CrossRefPubMed

43.

Dunet V, Rossier C, Buck A, Stupp R, Prior JO (2012) Performance of 18F-fluoro-ethyl-tyrosine (18F-FET) PET for the differential diagnosis of primary brain tumor: a systematic review and metaanalysis. J Nucl Med 53:207–214CrossRefPubMed

44.

Gempt J, Soehngen E, Forster S, Ryang YM, Schlegel J, Zimmer C et al (2014) Multimodal imaging in cerebral gliomas and its neuropathological correlation. Eur J Radiol 83:829–834CrossRefPubMed

45.

Dunkl V, Cleff C, Stoffels G, Judov N, Sarikaya-Seiwert S, Law I et al (2015) The usefulness of dynamic O-(2-18F-fluoroethyl)-l-tyrosine PET in the clinical evaluation of brain tumors in children and adolescents. J Nucl Med 56:88–92CrossRefPubMed

46.

Nedergaard MK, Kristoffersen K, Michaelsen SR, Madsen J, Poulsen HS, Stockhausen MT et al (2014) A. The use of longitudinal 18F-FET MicroPET imaging to evaluate response to irinotecan in orthotopic human glioblastoma multiforme xenografts. PLoS One 9:e100009CrossRefPubMedPubMedCentral

47.

Zhao F, Cui Y, Li M, Fu Z, Chen Z, Kong L et al (2014) Prognostic value of 3′-deoxy-3′-18F-fluorothymidine ([(18)F] FLT PET) in patients with recurrent malignant gliomas. Nucl Med Biol 41:710–715CrossRefPubMed

48.

Wardak M, Schiepers C, Cloughesy TF, Dahlbom M, Phelps ME, Huang SC (2014) (1)(8)F-FLT and (1)(8)F-FDOPA PET kinetics in recurrent brain tumors. Eur J Nucl Med Mol Imaging 41:1199–1209CrossRefPubMedPubMedCentral

49.

Oborski MJ, Demirci E, Laymon CM, Lieberman FS, Mountz JM (2014) Assessment of early therapy response with 18F-FLT PET in glioblastoma multiforme. Clin Nucl Med 39:e431–e432CrossRefPubMed

50.

Oborski MJ, Laymon CM, Lieberman FS, Drappatz J, Hamilton RL, Mountz JM (2014) First use of (18)F-labeled ML-10 PET to assess apoptosis change in a newly diagnosed glioblastoma multiforme patient before and early after therapy. Brain Behav 4:312–315CrossRefPubMedPubMedCentral

51.

Nensa F, Beiderwellen K, Heusch P, Wetter A (2014) Clinical applications of PET/MR: current status and future perspectives. Diagn Interv Radiol 20(5):438–447CrossRefPubMedPubMedCentral

52.

Puttick S, Bell C, Dowson N, Rose S, Fay M (2015) PET, MRI, and simultaneous PET/MRI in the development of diagnostic and therapeutic strategies for glioma. Drug Discov Today 20:306–317CrossRefPubMed

53.

Hutterer M, Hattingen E, Palm C, Proescholdt MA, Hau P (2014) Current standards and new concepts in MRI and PET response assessment of antiangiogenic therapies in high-grade glioma patients. Neuro Oncol 17(6):784–800CrossRefPubMed

54.

Preuss M, Werner P, Barthel H, Nestler U, Christiansen H, Hirsch FW et al (2014) Integrated PET/MRI for planning navigated biopsies in pediatric brain tumors. Childs Nerv Syst 30:1399–1403CrossRefPubMed

55.

Keen HG, Ricketts SA, Maynard J, Logie A, Odedra R, Shannon AM et al (2014) Examining changes in [18 F]FDG and [18 F]FLT uptake in U87-MG glioma xenografts as early response biomarkers to treatment with the dual mTOR1/2 inhibitor AZD8055. Mol Imaging Biol 16:421–430CrossRefPubMed

56.

Bell C, Rose S, Puttick S, Pagnozzi A, Poole CM, Gal Y et al (2014) Dual acquisition of (18)F-FMISO and (18)F-FDOPA. Phys Med Biol 59:3925–3949CrossRefPubMed

57.

Lapa C, Linsenmann T, Monoranu CM, Samnick S, Buck AK, Bluemel C, Czernin J, Kessler AF, Homola GA, Ernestus RI, Lohr M, Herrmann K et al (2014) Comparison of the amino acid tracers 18F-FET and 18F-DOPA in high-grade glioma patients. J Nucl Med 55(10):1611–1616CrossRefPubMed

58.

Zhang K, Langen KJ, Neuner I, Stoffels G, Filss C, Galldiks N et al (2014) Relationship of regional cerebral blood flow and kinetic behaviour of O-(2-(18)F-fluoroethyl)-l-tyrosine uptake in cerebral gliomas. Nucl Med Commun 35:245–251CrossRefPubMed

Title: Positron emission tomography of high-grade gliomas
Author: Guido Frosina
Publication date: 01-05-2016
Publisher: Springer US
Published in: Journal of Neuro-Oncology / Issue 3/2016
Print ISSN: 0167-594X
Electronic ISSN: 1573-7373
DOI: https://doi.org/10.1007/s11060-016-2077-1

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Positron emission tomography of high-grade gliomas

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2016

Brain tumour differentiation: rapid stratified serum diagnostics via attenuated total reflection Fourier-transform infrared spectroscopy

Erratum to: The optimal regimen of bevacizumab for recurrent glioblastoma: does dose matter?

Bevacizumab and temozolomide versus temozolomide alone as neoadjuvant treatment in unresected glioblastoma: the GENOM 009 randomized phase II trial

Brain metastasis in breast cancer: a comprehensive literature review

The challenges associated with molecular targeted therapies for glioblastoma

The optimal regimen of bevacizumab for recurrent glioblastoma: does dose matter?